High efficacy of the German multicenter ALL (GMALL) protocol for treatment of adult acute lymphoblastic leukemia (ALL) — a single-institution study |
| |
| Authors: | R. Scherrer P. Bettelheim K. Geissler U. Jäger P. Knöbl P. A. Kyrle K. Laczika G. Mitterbauer E. Neumann B. Schneider I. Schwarzinger K. Lechner |
| |
| Affiliation: | (1) First Medical Department, Division of Hematology and Blood Coagulation, University of Vienna, Währinger Gürtel 18-20, A-1090 Vienna, Austria;(2) Clinical Institute of Laboratory Diagnostics, University of Vienna, Vienna, Austria;(3) Institute of Medical Statistics and Documentation, University of Vienna, Vienna, Austria |
| |
| Abstract: | Summary Sixty-one consecutive patients with acute lymphoblastic leukemia (ALL) (B-ALL excluded) were treated with the protocol described by Hoelzer et al. [15]. The complete remission (CR) rate was 85% (52/61 patients). Three patients died during induction therapy; six patients were refractory to treatment. The median duration of continuous complete remission (CCR), disease-free survival (DFS), and overall survival was 41.5, 41.4, and 40.8 months, respectively. At 5 years the probability of CCR was 49%, of DFS 43.5%, and of overall survival 41.6%. In the univariate analysis older age (>35 years,p=0.01), bcr-abl positivity (p=0.007), and time to CR (>4 weeks,p=0.05) were significantly unfavorable prognostic factors. In the multivariate analysis only age (p=0.006) and time to CR (p = 0.02) remained significant. Thus, our data confirm the high efficacy of this treatment regimen with regard to CR rate and remission duration. |
| |
| Keywords: | Acute lymphoblastic leukemia Treatment Prognostic factors |
| 本文献已被 SpringerLink 等数据库收录！ |
|
